Earnings Per Common Share Attributable to Common Shareholders



The following table provides the detailed calculation of EPS:
	Three Months Ended				Nine Months Ended
(IN MILLIONS)	September 30, 2018		October 1, 2017		September 30, 2018		October 1, 2017
EPS Numerator––Basic
Income from continuing operations	$	4,111	$	2,858	$	11,562	$	9,064
Less: Net income attributable to noncontrolling interests	8		18		25		32
Income from continuing operations attributable to Pfizer Inc.	4,103		2,840		11,537		9,032
Less: Preferred stock dividends––net of tax	—		—		1		1
Income from continuing operations attributable to Pfizer Inc. common shareholders	4,103		2,839		11,536		9,032
Discontinued operations––net of tax	11		—		10		1
Net income attributable to Pfizer Inc. common shareholders	$	4,114	$	2,839	$	11,546	$	9,033
EPS Numerator––Diluted
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions	$	4,103	$	2,840	$	11,537	$	9,032
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions	11		—		10		1
Net income attributable to Pfizer Inc. common shareholders and assumed conversions	$	4,114	$	2,840	$	11,546	$	9,034
EPS Denominator
Weighted-average number of common shares outstanding––Basic	5,875		5,951		5,899		5,972
Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements	112		89		99		85
Weighted-average number of common shares outstanding––Diluted	5,986		6,041		5,998		6,057
Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans^(a)	5		47		3		47


^(a)	These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.